186 related articles for article (PubMed ID: 18540932)
1. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
Collin SM; Metcalfe C; Donovan J; Lane JA; Davis M; Neal D; Hamdy F; Martin RM
BJU Int; 2008 Nov; 102(10):1400-6. PubMed ID: 18540932
[TBL] [Abstract][Full Text] [Related]
2. PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study.
Patel DN; Feng T; Simon RM; Howard LE; Vidal AC; Moreira DM; Castro-Santamaria R; Roehrborn C; Andriole GL; Freedland SJ
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):238-244. PubMed ID: 29795141
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?
Avery KN; Metcalfe C; Blazeby JM; Lane JA; Neal DE; Hamdy FC; Donovan JL
BJU Int; 2008 Dec; 102(11):1629-33. PubMed ID: 18710456
[TBL] [Abstract][Full Text] [Related]
4. Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
Collin SM; Metcalfe C; Donovan JL; Athene Lane J; Davis M; Neal DE; Hamdy FC; Martin RM
Eur J Cancer; 2009 Dec; 45(18):3254-61. PubMed ID: 19541477
[TBL] [Abstract][Full Text] [Related]
5. Detection rate of prostate cancer using prostate specific antigen in patients presenting with lower urinary tract symptoms: a retrospective study.
Chavan PR; Chavan SV; Chavan NR; Trivedi VD
J Postgrad Med; 2009; 55(1):17-21. PubMed ID: 19242073
[TBL] [Abstract][Full Text] [Related]
6. The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial.
Frånlund M; Carlsson S; Stranne J; Aus G; Hugosson J
BJU Int; 2012 Sep; 110(5):638-43. PubMed ID: 22540895
[TBL] [Abstract][Full Text] [Related]
7. Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50-69 years with PSA ≥3 ng/ml.
Chandra Engel J; Palsdottir T; Aly M; Egevad L; Grönberg H; Eklund M; Nordström T
Scand J Urol; 2020 Feb; 54(1):1-6. PubMed ID: 31876229
[No Abstract] [Full Text] [Related]
8. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
Antunes AA; Srougi M; Dall'oglio MF; Vicentini F; Paranhos M; Freire GC
J Sex Med; 2008 Jul; 5(7):1702-7. PubMed ID: 18194186
[TBL] [Abstract][Full Text] [Related]
9. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men.
Sarma AV; Burke JP; Jacobson DJ; McGree ME; St Sauver J; Girman CJ; Lieber MM; Herman W; Macoska J; Montie JE; Jacobsen SJ
Diabetes Care; 2008 Mar; 31(3):476-82. PubMed ID: 18071006
[TBL] [Abstract][Full Text] [Related]
10. Reduction of prostate-specific antigen after tamsulosin treatment in patients with elevated prostate-specific antigen and lower urinary tract symptoms associated with low incidence of prostate cancer at biopsy.
Tubaro A; De Nunzio C; Mariani S; Trucchi A; Miano R; Vicentini C; Miano L
Urology; 2010 Aug; 76(2):436-41. PubMed ID: 20538320
[TBL] [Abstract][Full Text] [Related]
11. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
Chung BH; Hong SJ; Cho JS; Seong DH
BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
[TBL] [Abstract][Full Text] [Related]
12. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
[TBL] [Abstract][Full Text] [Related]
13. The significance of a high preoperative PSA level for the detection of incidental prostate cancer in LUTS patients with large prostates.
Magistro G; Keller P; Westhofen T; Schott M; Tamalunas A; Weinhold P; Stief CG
World J Urol; 2021 May; 39(5):1481-1487. PubMed ID: 32588205
[TBL] [Abstract][Full Text] [Related]
14. The diagnostic value of abdominal ultrasound, urine cytology and prostate-specific antigen testing in the lower urinary tract symptoms clinic.
Patel NS; Blick C; Kumar PV; Malone PR
Int J Clin Pract; 2009 Dec; 63(12):1734-8. PubMed ID: 19930334
[TBL] [Abstract][Full Text] [Related]
15. [The changes of prostate specific antigen (PSA) after treatment with alpha 1-adrenergic receptor antagonists in men with 4.0-9.9 ng/ml PSA level--a study for comparison of benign prostatic hyperplasia/lower urinary tract symptom (BPH/LUTS) and prostate cancer].
Hanai T; Matsumoto S; Shouji S; Usui Y; Tang XY; Kato Y; Iguchi M; Uemura H; Terachi T
Hinyokika Kiyo; 2009 Apr; 55(4):187-91. PubMed ID: 19462822
[TBL] [Abstract][Full Text] [Related]
16. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA
JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892
[TBL] [Abstract][Full Text] [Related]
17. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.
Gratzke C; Bachmann A; Descazeaud A; Drake MJ; Madersbacher S; Mamoulakis C; Oelke M; Tikkinen KAO; Gravas S
Eur Urol; 2015 Jun; 67(6):1099-1109. PubMed ID: 25613154
[TBL] [Abstract][Full Text] [Related]
18. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting.
Naslund MJ; Gilsenan AW; Midkiff KD; Bown A; Wolford ET; Wang J
Int J Clin Pract; 2007 Sep; 61(9):1437-45. PubMed ID: 17686091
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
